Buntanetap Market Size, Forecast, and Emerging Insight - 2032

This “Buntanetap Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about buntanetap for Parkinson's disease in the seven major markets. A detailed picture of the buntanetap for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the buntanetap for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the buntanetap market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary

Buntanetap (previously known as ANVS401 or posiphen) is a synthetically produced oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which lowers the level of neurotoxic proteins and consequently less toxicity in the brain. Buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins - APP/Aβ (APP), tau/phospho-tau (tau), and α-Synuclein (αSYN) - that is one of the main causes of neurodegeneration at once and improve motor function.

The US FDA has green-lighted the continued development of Buntanetap into phase III for early and advanced Parkinson's disease. Presently buntanetap is being studied in a Phase III early Parkinson's disease study and the company expects to complete the trial by the end of 2023. The company is also developing buntanetap for Alzheimer's disease and other neurodegenerative conditions.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the buntanetap description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on buntanetap regulatory milestones and other development activities have been provided in this report.
• The report also highlights the buntanetap research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around buntanetap.
• The report contains forecasted sales of buntanetap for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for buntanetap in Parkinson's disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Buntanetap Analytical Perspective

In-depth Buntanetap Market Assessment

This report provides a detailed market assessment of buntanetap for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

Buntanetap Clinical Assessment

The report provides the clinical trials information of buntanetap for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence buntanetap dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to buntanetap and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of buntanetap in Parkinson's disease.
• This in-depth analysis of the forecasted sales data of buntanetap from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the buntanetap in Parkinson's disease.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of buntanetap?
• What is the clinical trial status of the study related to buntanetap in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the buntanetap development?
• What are the key designations that have been granted to buntanetap for Parkinson's disease?
• What is the forecasted market scenario of buntanetap for Parkinson's disease?
• What are the forecasted sales of buntanetap in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to buntanetap for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

This product will be delivered within 2 business days.